期刊文献+

96例异基因造血干细胞移植后5年总生存率的危险因素分析 被引量:2

Analysis of Risk Factors for Overall Survival at 5 Years in 96 Patients after Allogeneic Hematopoietic Cell Transplantation
下载PDF
导出
摘要 本研究探索96例异基因造血干细胞移植(allo-HSCT)后5年总生存的主要危险因素,以便早期采取积极有效的防治措施,更好地提高移植疗效。对96例allo-HSCT患者的资料进行回顾性分析。选择年龄、性别、移植时疾病状态、HLA配型、供者类型、供受者血型、预处理方案、急性移植物抗宿主病(aGVHD)、出血性膀胱炎(HC)、肝静脉闭塞(VOD)、间质性肺炎(IP)等11个临床参数,进行Cox单因素分析。将在单因素分析中p<0.1作为有统计学意义的因素进行Cox多因素回归分析。aGVHD的累积发生率和患者的生存率采用Kaplan-Meier曲线计算。结果表明:除1例患者造血干细胞未植活外,其余95例患者均达到稳定植活,ANC≥0.5×109/L的中位时间为移植后13天。96例中有42例发生Ⅰ-Ⅳ度aGVHD(43.75%),其中Ⅰ度11例(11.46%),Ⅱ度19例(19.79%);Ⅲ-Ⅳ度12例(12.50%)。96例接受移植的患者中复发10例,死亡38例,5年的总生存(OS)率为60.42%。Cox模型分析表明,aGVHD和移植前的疾病状态是影响患者长期生存率的主要因素,其相对危险度分别是2.996和2.619。结论:影响患者长期生存的主要危险因素是aGVHD和移植前的疾病状态,提高allo-HSCT疗效的关键是控制aGVHD,同时要把握好移植时机的选择,对于有高危复发因素的患者应争取在CR1期进行allo-HSCT。 The aim of this study was to analyze the risk factors for overall survival at 5 years in 96 patients undergoing allogeneic hematopoietic stem cell transplantation by retrospective analysis. 11 clinical parameters including age, sex, disease status, HLA locus, donor type, donor-recipient blood type, conditioning regimen, aGVHD, HC, VOD and IP were selected for univariate analysis by using a Cox regression. Factors have statistic significance at the 0. 1 level on univariate analysis were evaluated by multivariate analysis by a Coxs regression. The cumulative incidence of aGVHD and survival rate of patients were calculated by the method of Kaplan and Meier. The results showed that 95 patients achieved sustained donor engraftment except 1 patients. The median time of leukocyte engraftment (ANC ≥0.5×10^9/L) was 13 days. The aGVHD of Ⅰ-Ⅳ grade was observed in 42 out of 96 patients (43.75%), in which 11 patients were with aGVHD of Ⅰgrade ( 11.46% ), 19 patients were with aGVHD of Ⅱ grade ( 19.79% ), 12 patients were with aGVHD of Ⅲ-Ⅳ grade ( 12.50% ). Out of 96 patients 10 relapsed and 38 dead, the overall survival at 5 years was 60.42%. The Cox regression analysis showed that aGVHD and disease status before transplant were main factors affecting long-term survival of patients, relative risks of which were 2. 996 and 2. 619 respectively. It is concluded that the main factors affecting long-term survival of patients are aGVHD and disease status. The key to improve the outcome of allo-HSCT is to reduce the incidence and severity of aGVHD, meanwhile to select the CR1 for allo-HSCT to treat the patients in advanced refractory and relapsed situation should be considered as important risk factors.
出处 《中国实验血液学杂志》 CAS CSCD 2009年第3期713-718,共6页 Journal of Experimental Hematology
关键词 异基因造血干细胞移植 移植物抗宿主病 总生存率 危险因素分析 allo-HSCT GVHD overall survival risk factor analysis
  • 相关文献

参考文献21

  • 1Heslop HE.Haemapoietic stem cell transplantation from unrelated donors.Br J Haematol,1999, 105:2-6
  • 2陈育红,黄晓军,陈欢,许兰平,刘代红,江倩,张耀臣,韩伟,高志勇,王景枝,刘开彦,吴彤,陆道培.非血缘关系异基因造血干细胞移植66例分析[J].中华血液学杂志,2005,26(11):656-660. 被引量:19
  • 3Baron F,Storb R.Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies, a review.Springer Semin Immunpathol,2004, 26:71 -94
  • 4陈育红,黄晓军,郭乃榄,任汉云,张耀臣,许兰平,高志勇,陆道培.异基因造血干细胞移植后急性移植物抗宿主病的发生及其危险因素的探讨[J].中华血液学杂志,2003,24(2):61-63. 被引量:45
  • 5Nash RA,Antin JH,Karanes C,et al.Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.Blood,2000,96:2062 -2068
  • 6Ratanatharathom V,Nash RA,Przepiorka D,et al.Phase Ⅲ study comparing methotrexate and tacrolimus (Prograf,FK506) with metho-trexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation.Blood,1998,92:2303-23014
  • 7Loren AW,Luger SM,Stadtmauer EA,et al.Intensive graftversus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.Boon Marrow Tran Splant,2005 ,35:921 -926
  • 8赖悦云,郭乃榄,黄晓军,许兰平,陈欢,汪素琴,郑海音,黎燕,沈倍奋,陆道培.免疫毒素去除T细胞在异基因造血干细胞移植中的应用[J].中国实验血液学杂志,2004,12(3):270-273. 被引量:2
  • 9Bacigalupo A.Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis, efficacy and side effects.Boon Marrow Transplant,2005,35:225 -231
  • 10Marmont AM,Horowitz MM,Gale RP,et al.T-cell depletion of HLA identical transplants in leukemia.Blood,1991, 78:2120 -2130

二级参考文献28

  • 1陈欢,郭乃榄,郑缓,卢锡京,王逸兰,史琪,吴彤,范韫明,黄晓军,张耀臣,许兰萍,陆道培.应用胎肝与胎胸腺输注预防移植物抗宿主病[J].中华血液学杂志,1996,17(2):73-75. 被引量:3
  • 2Storb R,Deeg H,Farewell V,et al.Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporin for prevention of acute graft versus host disease.Blood,1986; 68:119 - 125
  • 3Bachar-Lustig E,Reich-Zeliger S,Gur H,et al.Bone marrow transplantation across major genetic barriers: the role of megadose stem cells and nonalloreactive donor anti-third party CTLS.Transplant Proc,2001; 33:2099 - 2100
  • 4Handgretinger R,Schumm M,Lang P,et al.Transplantation of megadose of purified haploidentical stem cell.Ann N Y Acad Sci,1999; 872:351 - 362
  • 5Muller S,Schulz A,Reiss U,et al.Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children.Bone Marrow Transplant,1999; 24:575 - 581
  • 6Ho VT,Soiffer RJ.The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.Blood,2001; 98:3192-3204
  • 7Lamb LS Jr,Szafer F,Henslee Downey PJ,et al.Characterization of acute bone marrow graft rejection in T cell depleted partially mismatched related donor bone marrow transplantation.Exp Hematol,1995; 23:1595 - 1600
  • 8Soiffer RJ,Manch P,Tarbell NJ,et al.Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-idendical T celldepleted allogeneic marrow.Bone marrow transplant,1991; 7:23-33
  • 9Rachamim N,Gan J,Reisner Y,et al.Tolerance induction by ""megadose"" hematopoietic transplants.Transplantation,1998; 65:1386 - 1393
  • 10Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant,2000, 26: 397-404.

共引文献67

同被引文献44

  • 1陈瑶,陆道培,刘开彦,董陆佳,任汉云,黄晓军,陈欢,刘代红,江倩,陈育红,许兰平,张耀臣,路瑾,高志勇.异基因造血干细胞移植后急性移植物抗宿主病151例危险因素分析[J].中华血液学杂志,2005,26(2):74-77. 被引量:29
  • 2王书红,达万明,靳海杰,靖域,颜光涛.急性移植物抗宿主病病人血清IL-2、IL-8、IL-10及TNF-α水平变化的研究[J].中国实验血液学杂志,2006,14(4):755-758. 被引量:10
  • 3高晓东,吴文,唐帏,闫骅,徐岚,沈志祥,胡炯,赵维莅.造血干细胞移植患者血清IL-2及其受体检测的临床意义[J].中国实验诊断学,2006,10(12):1477-1479. 被引量:2
  • 4刘跃均,吴德沛,李彩霞,曹俊杰,仇惠英,马骁,吴小津,张学光.移植物中CD4^+CD25^+T细胞的表达与异基因造血干细胞移植后移植物抗宿主病的相关性[J].中华器官移植杂志,2007,28(6):371-372. 被引量:1
  • 5中华人民共和国科学技术部.关于善待实验动物的指导性意见.2006.09-30
  • 6Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stern cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756-763.
  • 7Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998; 16(8): 2817-2824.
  • 8Carella AM, Lerma E, Dejana A, et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica. 1998;83(10):904-909.
  • 9Banna GL, Aversa S, Sileni VC, et al. Nonmyeloablative allogeneic stem cell transplantation (NST) alter truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol. 2004;51 (3): 171-189.
  • 10Soliman GA. The mammalian target of rapamycin signaling network and gene regulation. Curr Opin Lipidol,2005; 16(3):317-323.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部